Volrustomig + Casdatifan + Nivolumab + Ipilimumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Clear Cell Renal Cell Carcinoma
Conditions
Advanced Clear Cell Renal Cell Carcinoma
Trial Timeline
Jul 28, 2025 → Jul 29, 2032
NCT ID
NCT07000149About Volrustomig + Casdatifan + Nivolumab + Ipilimumab
Volrustomig + Casdatifan + Nivolumab + Ipilimumab is a phase 3 stage product being developed by AstraZeneca for Advanced Clear Cell Renal Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT07000149. Target conditions include Advanced Clear Cell Renal Cell Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07000149 | Phase 3 | Active |
Competing Products
20 competing products in Advanced Clear Cell Renal Cell Carcinoma